Yes, you can microdose DMT, and a small but growing body of research suggests sub-hallucinogenic doses may produce measurable effects on mood and anxiety. However, DMT remains a Schedule I substance in the United States at the federal level, and there are no scientifically established dose ranges accepted for microdosing any psychedelic. What exists is a mix of animal research, early human pharmacology data, and a shifting legal landscape that makes this a topic worth understanding carefully.
What a DMT Microdose Actually Means
Microdosing any psychedelic generally means taking 5 to 10 percent of a standard hallucinogenic dose on a recurring schedule, typically every other day or every third day. The goal is to stay well below the threshold where you’d experience visual distortions, altered perception, or any sense of being “high.” For DMT specifically, the numbers get tricky because the drug is usually studied intravenously in clinical settings, not in the oral or vaporized forms people use outside labs.
In human IV studies, 0.2 mg/kg was the lowest dose that reliably produced hallucinogenic effects. A sub-hallucinogenic dose of 0.1 mg/kg produced noticeable but non-psychedelic effects, including what researchers described as an apparent anxiolytic (anxiety-reducing) response. A true microdose would fall even lower, somewhere around 0.01 to 0.02 mg/kg if following the 5-to-10-percent rule, though no clinical trial has validated a specific oral or inhaled microdose range for humans.
How DMT Works at Low Doses
DMT activates serotonin 2A receptors, the same target responsible for the effects of psilocybin and LSD. What makes psychedelics distinct from serotonin itself is where they act on these receptors. Research published in Science found that psychedelics, including DMT, activate serotonin 2A receptors located inside brain cells, not just on the cell surface. This intracellular activation is what drives their ability to promote neuroplasticity, the brain’s capacity to form new neural connections. Serotonin, despite activating the same type of receptor on the cell surface, doesn’t trigger the same growth effects.
DMT is relatively lipophilic compared to serotonin, meaning it passes through cell membranes more easily. This membrane permeability is a key reason it can reach those interior receptors. At sub-hallucinogenic doses, DMT may still engage these plasticity-promoting pathways without producing the dramatic perceptual shifts of a full dose, though the extent of this effect in humans at microdose levels hasn’t been directly measured.
What Animal Studies Show
The most detailed microdosing data comes from a rodent study that administered low doses of DMT (1 mg/kg) every third day for approximately two months. The rats showed antidepressant-like behavior and improved fear extinction learning, which is the brain’s ability to unlearn a fear response. Importantly, these benefits appeared without the anxiety-producing effects seen at higher doses (10 mg/kg), and working memory and social interaction remained unaffected.
The same research group found that chronic microdosing at this level did not alter levels of BDNF (a protein involved in nerve cell growth) or change the density of serotonin 2A receptors in the rats’ brains, yet the behavioral improvements persisted. This suggests the mechanism behind microdosing benefits may be more subtle than simply ramping up receptor activity or growth factor production.
DMT’s Unusually Short Duration
One feature that sets DMT apart from other psychedelics is how fast your body clears it. When administered intravenously, DMT reaches peak blood levels within about 2 minutes and has a plasma half-life of only 9 to 12 minutes. Psychedelic effects, when they occur at full doses, resolve within roughly 30 minutes. Compare that to psilocybin (4 to 6 hours) or LSD (8 to 12 hours), and DMT operates on a completely different timescale.
Your body breaks DMT down primarily through an enzyme called MAO-A, converting it into an inactive metabolite. This rapid metabolism is also why DMT is nearly inactive when swallowed on its own. Stomach enzymes destroy it before it reaches the brain in meaningful amounts. Ayahuasca solves this problem by combining DMT-containing plants with plants rich in MAO inhibitors (harmine and harmaline), which block the enzyme and extend DMT’s effects to 4 to 6 hours. Anyone considering oral DMT microdoses would face this same bioavailability problem: without an MAO inhibitor, very little DMT survives digestion.
Cardiovascular Considerations
At full doses, DMT consistently raises blood pressure and heart rate in a dose-dependent manner. In one study, a 0.3 mg/kg IV dose pushed peak blood pressure to 147/80 mmHg and heart rate to 96 beats per minute. Higher bolus doses have produced systolic readings near 160 mmHg and heart rates above 115 bpm, though these spikes are transient and resolve as the drug clears.
At sub-hallucinogenic doses, these cardiovascular effects are smaller but not absent. The 0.1 mg/kg dose still produced measurable increases in blood pressure and heart rate. For microdoses well below that threshold, cardiovascular data simply doesn’t exist yet. Researchers have noted there is insufficient evidence on the cardiovascular safety of psychedelic microdosing specifically, and no data at all on safety for people with pre-existing heart conditions.
Legal Status
DMT is classified as a Schedule I controlled substance under U.S. federal law, making possession, sale, and manufacture illegal regardless of the amount or intended use. This classification has not changed.
At the state and local level, the picture is more complex. Colorado’s Proposition 122, passed in November 2022, decriminalized the personal possession of several psychedelic substances including DMT for adults 21 and older and established a framework for regulated therapeutic access. California’s SB-58, which proposed making possession of DMT, psilocybin, and mescaline lawful for personal use by adults 21 and older starting January 2025, was vetoed by the governor. Several cities, including Oakland, Santa Cruz, and San Francisco, have passed resolutions deprioritizing enforcement of psychedelic possession laws, though these are policy directives rather than changes to the legal code.
Oregon legalized regulated psilocybin therapy through Measure 109 in 2020 but did not extend this to DMT. No U.S. jurisdiction currently offers a legal, regulated pathway for DMT microdosing outside of approved clinical research.
How DMT Microdosing Compares to Other Psychedelics
Most microdosing research and community experience centers on psilocybin and LSD, both of which are orally active without any additional compounds and have durations measured in hours. DMT’s rapid metabolism creates practical challenges that those substances don’t share. Taking DMT orally without an MAO inhibitor means almost none reaches your brain. Taking it with an MAO inhibitor essentially creates a homemade ayahuasca analog, which introduces its own risks: MAO inhibitors interact dangerously with many common medications and certain foods containing tyramine.
Vaporized DMT bypasses the digestion problem entirely, delivering the compound directly to the bloodstream through the lungs. This is the route most commonly discussed in microdosing communities, though precisely measuring a sub-milligram vaporized dose is technically difficult and no standardized method exists. The margin between “nothing noticeable” and “unexpected psychedelic experience” can be very narrow with an inhaled route, making consistent microdosing harder to achieve than with a substance like psilocybin that can be weighed into capsules.
For people drawn to DMT-related microdosing, some opt for low-dose ayahuasca or ayahuasca analogs, which offer more predictable oral absorption and a longer, gentler curve of effects. This shifts the pharmacology significantly, though, since the MAO inhibitor component has its own psychoactive and physiological effects independent of DMT.